Effect of tirofiban combined with dual-antibody therapy on patients with disabling minor ischemic stroke
Objective To investigate the effect of tirofiban combined with dual-antibody therapy on adverse cardiovascular and cerebrovascular events and recurrence in patients with disabling minor ischemic stroke.Methods The clinical data of 154 patients with disabling minor ischemic stroke admitted to Haian People's Hospital from March 2021 to June 2023 were retrospectively analyzed.The patients were divided into two groups according to different treatment approaches,with 77 in each group.The patients in the control group were given conventional antiplatelet therapy while those in the observation group underwent tirofiban adjuvant therapy based on the treatment regimen in the control group.Then the clinical efficacy,National Institutes of Health stroke scale(NIHSS),Modified Rankin Scale(mRS),changes in platelet parameters,adverse cardiovascular and cerebrovascular events and recurrence were compared between the two groups.Results There was no statistically significant difference in the treatment effective rate between the observation group(92.20%(71/77))and the control(83.16%(64/77))(χ2=2.942,P>0.05).In terms of NIHSS and mRS scores,all patients in the two groups showed a decrease after treatment,and they were lower in the observation group than in the control((1.13±0.19)points vs(1.36±0.21)points,(1.30±0.33)points vs(1.62±0.35)points,t=7.126,5.837,both P<0.05).The observation group had smaller mean platelet volume(MPV)and platelet distribution width(PDW)and larger plateletcrit(PCT)as compared with the control((9.15±1.26)flvs(11.03±1.35)fl,(12.14±1.63)%vs(13.28±1.67)%,(0.35±0.06)%vs(0.28±0.04)%,t=8.933,4.286,8.518,all P<0.05).The adverse cardiovascular and cerebrovascular event rate and recurrence rate of the observation group were 6.49%(5/77)and 3.89%(3/77)but those of the control were 12.98%(10/77)and 7.79%(6/77),showing no statistical difference between the two groups(χ2=1.847,0.472,both P>0.05).Conclusion Application of tirofiban combined with dual-antibody therapy in patients with disabling minor ischemic stroke can effectively improve neurological and platelet function and prognosis.Furthermore,there is no major increase in incidence of adverse cardiovascular and cerebrovascular events.
Disabling minor ischemic strokeTirofibanAdverse cardiovascular and cerebrovascular eventRecurrenceNeurological functionPlatelet function
NETL
NSTL
万方数据
